MeSH term
Frequency | Condition_Probility | Animals | 15 | 0.0 |
Epinephrine/blood | 2 | 1.0 |
Humans | 24 | 0.0 |
Male | 24 | 0.0 |
Norepinephrine/blood | 2 | 1.0 |
Rats | 10 | 0.0 |
Rats, Wistar | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 21 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 4 | 0.0 |
Adult | 13 | 0.0 |
Corticotropin/blood | 4 | 2.0 |
Double-Blind Method | 3 | 0.0 |
Hydrocortisone/blood | 4 | 0.0 |
Hypothalamo-Hypophyseal System/*drug effects | 2 | 10.0 |
Neurosecretory Systems/*physiopathology | 2 | 11.0 |
Chromosomes, Human, Pair 1/*genetics | 3 | 1.0 |
Gene Deletion | 2 | 0.0 |
Neuroblastoma/*genetics/pathology | 2 | 6.0 |
Tumor Cells, Cultured | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Cortisone/blood | 2 | 28.0 |
Time Factors | 4 | 0.0 |
Corticosterone/blood | 3 | 8.0 |
Adolescent | 3 | 0.0 |
Female | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 7 | 0.0 |
Mice | 2 | 0.0 |
Hydrocortisone/*blood | 3 | 2.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Middle Aged | 3 | 0.0 |
Testosterone/blood | 2 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Prolactin/*blood | 2 | 0.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Comparative Study | 4 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
Receptors, Glucocorticoid/*metabolism | 2 | 7.0 |
Administration, Oral | 2 | 0.0 |
Corticosterone/*blood | 3 | 37.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Corticotropin/*blood | 2 | 3.0 |
Growth Hormone/*blood | 2 | 1.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Electroencephalography | 2 | 0.0 |
